AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical...

Related Keywords

Denmark ,Japan ,Tokyo ,Netherlands ,Copenhagen ,Køavn ,New Jersey ,United States ,Mohamed Zaki ,Instagram ,Macrophage Propertiesj Immunol ,Linkedin ,Twitter ,Exchange Commission ,Hodgkin Lymphoma Research Foundation ,Youtube ,Us National Library Of Medicine ,Development Of Novel Anti ,Allergan ,Facebook ,Diffuse Large Lymphoma Research Foundation ,Company Announcement ,Largeb Cell ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Annual Report ,Y Shaped Genmab ,Largeb Cell Lymphoma ,Research Foundation ,Hodgkin Lymphoma ,Rev Oncol ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Sci Ther ,Abbvie ,